Federation Des Caisses Desjardins Du Quebec Galmed Pharmaceuticals Ltd. Transaction History

Federation Des Caisses Desjardins Du Quebec

  • $18.9 Billion
  • Q3 2024

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2024
SELL
$0.29 - $5.21 $725 - $13,025
-2,500 Closed
0 $0
Q1 2022

Aug 14, 2024
BUY
$1.23 - $2.07 $3,075 - $5,175
2,500 New
2,500 $3.98 Million
Q2 2021

Aug 30, 2024
BUY
$2.24 - $3.9 $5,600 - $9,750
2,500 New
2,500 $7.6 Million
Q1 2021

Aug 30, 2024
BUY
$3.19 - $5.4 $7,975 - $13,500
2,500 New
2,500 $8.58 Million
Q4 2020

Aug 30, 2024
SELL
$3.06 - $4.17 $3,060 - $4,170
-1,000 Closed
0 $0
Q4 2018

Aug 30, 2024
BUY
$6.59 - $14.47 $6,590 - $14,470
1,000 New
1,000 $6.83 Million
Q2 2018

Aug 30, 2024
BUY
$5.04 - $17.96 $5,040 - $17,960
1,000 New
1,000 $11.9 Million

About Galmed Pharmaceuticals Ltd.

GLMD Quotes by TradingView
  • Ticker GLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,088,400
  • Market Cap $73.5M
  • Description
  • Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or t...
More about GLMD
Track This Portfolio

Track Federation Des Caisses Desjardins Du Quebec Portfolio

Follow Federation Des Caisses Desjardins Du Quebec and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email